PD-1抑制剂联合地西他滨治疗复发难治性灰区淋巴瘤1例

图 1 PD-1抑制剂（信迪利单抗）联合地西他滨方案治疗前后肝脏病灶的变化

A，B：PD-1抑制剂联合地西他滨方案治疗前；C，D：2个周期化疗后；E，F：4个周期化疗后

下载: 全尺寸图片幻灯片

[1]	Terao T, Yuda J, Yamauchi N, et al. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone l ymphoma with long-term remission[J]. Mol Clin Oncol, 2021, 14(6):125. doi: 10.3892/mco.2021.2287
[2]	Pilichowska M, Kritharis A, Evens AM. Gray zone lymphoma: current diagnosis and treatment options[J]. Hematol Oncol Clin North Am, 2016, 30(6):1251-1260. doi: 10.1016/j.hoc.2016.07.006
[3]	Melani C, Major A, Schowinsky J, et al. PD-1 blockade in mediastinal gray-zone lymphoma[J]. N Engl J Med, 2017, 377(1):89-91. doi: 10.1056/NEJMc1704767
[4]	Liu Y, Wang C, Li X, et al. Improved clinical outcome in a randomized phase Ⅱ study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma[J]. J Immunother Cancer, 2021, 9(4):e002347. doi: 10.1136/jitc-2021-002347